[New aspects in the treatment of neovascular age-related macular degeneration: the criteria of re-treatment with the anti-VEGF therapy.].
D
D
Pauleikhoff
B
B
Kirchhof
B
B
Bertram
F G
FG
Holz
U B
UB
Bartz-Schmidt
N
N
Bornfeld
M
M
Bresgen
H
H
Heimann
H
H
Helbig
H
H
Hörauf
A
A
Kampik
K D
KD
Lemmen
J
J
Roider
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D005858:Germany; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D009885:Ophthalmology / Q000592:standards* / Q000639:trends*; D017410:Practice Guidelines as Topic; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D001688:Biological Products; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A